12 Best Short Squeeze Stocks to Buy Right Now

Page 1 of 12

In this article, we will take a look at the 12 Best Short Squeeze Stocks to Buy Right Now.

As the year comes to a close, investors are keeping close tabs on the Federal Reserve’s impending policy move, given the US shutdown-induced data shortage. Following the delayed September retail sales and wholesale inflation numbers, which fell short, markets are estimating a December quarter-point rate decrease with a likelihood exceeding 80%. Labor market indicators also reflect weakening, which may encourage officials to make cuts.

Meanwhile, politics at the central bank continue to heat up, with five candidates on President Trump’s shortlist to succeed Chair Jerome Powell next year.

In such a climate, several banks forecast strong market growth for the S&P 500 in the following year. In a revised outlook issued on November 25, Deutsche Bank set a price goal of 8,000 for the benchmark index at the end of 2026, citing “mid-teens returns” from greater inflows, buybacks, and ongoing earnings strength. Wells Fargo had similar comments, predicting a two-stage rally next year as the market transitions from a “reflation hope” trade in the first half to a greater AI-driven rise in the second half.

Our Methodology

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant short interest. From that list, we primarily chose stocks with a short float of 20% or above. Additionally, we have mentioned the hedge fund sentiment around each stock, as of Q3 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

12. CRISPR Therapeutics AG (NASDAQ:CRSP)

short % of float: 23.03%

Number of Hedge Fund Holders: 21

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. The firm discussed positive findings from CRISPR’s American Heart Association presentation on CTX310, targeted at ANGPTL3 for a variety of cholesterol issues.

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some major catalysts, including in-vivo cardiovascular and alpha-1 antitrypsin deficiency updates in 2026, as well as a pediatric review for Casgevy at the American Society of Hematology meeting in 2025.

In addition, CRISPR’s third-quarter Casgevy sales fell short of forecasts, totaling $17 million compared to a consensus estimate of $41 million, with infusions falling from 16 in the second quarter to 10 in the current quarter. Nonetheless, CRISPR Therapeutics AG (NASDAQ:CRSP) remains confident about the Casgevy launch, citing increased cell collection numbers (45 vs. 25 in the second quarter) and a new reimbursement arrangement with Italy.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification.

Page 1 of 12